Trial Profile
A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Topotecan (Primary) ; HM 30181A
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Athenex
- 28 Jul 2021 Status changed from recruiting to completed.
- 14 Jun 2019 Status changed from planning to recruiting.
- 03 Apr 2017 New trial record